147 related articles for article (PubMed ID: 12951277)
1. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy.
Nakamura N; Hasegawa G; Obayashi H; Yamazaki M; Ogata M; Nakano K; Yoshikawa T; Watanabe A; Kinoshita S; Fujinami A; Ohta M; Imamura Y; Ikeda T
Diabetes Res Clin Pract; 2003 Aug; 61(2):93-101. PubMed ID: 12951277
[TBL] [Abstract][Full Text] [Related]
2. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment.
Tomé CC; De Rojas Silva MV; Rodríguez-García J; Rodríguez-Segade S; Sánchez-Salorio M
Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1272-6. PubMed ID: 15947940
[TBL] [Abstract][Full Text] [Related]
3. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
4. Role of N-ε- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus.
Choudhuri S; Dutta D; Sen A; Chowdhury IH; Mitra B; Mondal LK; Saha A; Bhadhuri G; Bhattacharya B
Mol Vis; 2013; 19():100-13. PubMed ID: 23378723
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
[TBL] [Abstract][Full Text] [Related]
6. Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.
Fokkens BT; Mulder DJ; Schalkwijk CG; Scheijen JL; Smit AJ; Los LI
PLoS One; 2017; 12(3):e0173379. PubMed ID: 28264049
[TBL] [Abstract][Full Text] [Related]
7. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy.
Matsumoto Y; Takahashi M; Ogata M
Jpn J Ophthalmol; 2002; 46(4):406-12. PubMed ID: 12225819
[TBL] [Abstract][Full Text] [Related]
8. Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes.
Sato E; Nagaoka T; Yokota H; Takahashi A; Yoshida A
Am J Ophthalmol; 2012 May; 153(5):903-909.e1. PubMed ID: 22265156
[TBL] [Abstract][Full Text] [Related]
9. Levels of mature cross-links and advanced glycation end product cross-links in human vitreous.
Matsumoto Y; Takahashi M; Chikuda M; Arai K
Jpn J Ophthalmol; 2002; 46(5):510-7. PubMed ID: 12457909
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy.
Katagiri M; Shoji J; Inada N; Kato S; Kitano S; Uchigata Y
Int Ophthalmol; 2018 Apr; 38(2):607-615. PubMed ID: 28299499
[TBL] [Abstract][Full Text] [Related]
11. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
12. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous].
Hashimoto H; Arai K; Chikuda M; Obara Y
Nippon Ganka Gakkai Zasshi; 1998 Jul; 102(7):442-6. PubMed ID: 9720366
[TBL] [Abstract][Full Text] [Related]
14. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
[TBL] [Abstract][Full Text] [Related]
15. Pentosidine - a new biochemical marker in diabetic retinopathy.
Salman AG; Mansour DE; Swelem AH; Al-Zawahary WM; Radwan AA
Ophthalmic Res; 2009; 42(2):96-8. PubMed ID: 19546600
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
17. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy.
Koskela UE; Kuusisto SM; Nissinen AE; Savolainen MJ; Liinamaa MJ
Ophthalmic Res; 2013; 49(2):108-14. PubMed ID: 23257933
[TBL] [Abstract][Full Text] [Related]
18. Effect of age and menopause on serum concentrations of pentosidine, an advanced glycation end product.
Takahashi M; Oikawa M; Nagano A
J Gerontol A Biol Sci Med Sci; 2000 Mar; 55(3):M137-40. PubMed ID: 10795725
[TBL] [Abstract][Full Text] [Related]
19. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia?
Hein G; Franke S
Rheumatology (Oxford); 2002 Oct; 41(10):1163-7. PubMed ID: 12364637
[TBL] [Abstract][Full Text] [Related]
20. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy.
Lange CAK; Stavrakas P; Luhmann UFO; de Silva DJ; Ali RR; Gregor ZJ; Bainbridge JWB
Am J Ophthalmol; 2011 Sep; 152(3):406-412.e3. PubMed ID: 21723532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
